Article
Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
AIDS (London, England) - 1 Oct 1997
Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann O T, von Overbeck J, Leduc D, Perrin L, Hirschel B
Abstract excerpt
OBJECTIVE: To assess the safety, efficacy and plasma drug levels of the combination of ritonavir plus saquinavir for the treatment of advanced HIV infection. DESIGN: Multicentre pilot study. PATIENTS: Eighteen protease inhibitor-naive patients, with intolerance or contraindication to reverse transcriptase inhibitors, a median CD4 cell count of 12 x 10(6)/l (range, 1-50 x 10(6)/l), and a median HIV viraemia of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.